Orforglipron pill tested in Chinese adults with obesity or overweight
Tests a daily pill, orforglipron, against a dummy pill in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Key facts
- Where
- Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing, and Shanghai, ChinaSee the 13 sites
- Phase
- Phase 3
Where in China
- Sichuan Provincial People's HospitalChengdu, ChinaNo longer taking part
- Zhujiang HospitalGuangzhou, ChinaNo longer taking part
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
- Zhejiang Provincial People's HospitalHangzhou, ChinaNo longer taking part
- The Fourth Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
- The Second People's Hospital of HefeiHefei, ChinaNo longer taking part
- Jinan Central HospitalJinan, ChinaNo longer taking part
- The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang Shi, ChinaNo longer taking part
- Jiangxi Provincial People's HospitalNanchang, ChinaNo longer taking part
- Jiangsu Province HospitalNanjing, ChinaNo longer taking part
- Nanjing First HospitalNanjing, ChinaNo longer taking part
- The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaNo longer taking part
- Shanghai Sixth People's HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07790861
- Record updated
- 13 October 2026
- Original description
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
Inclusion: Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and <30 kg/m2 or ≥24.0 kg/m2 and <28 kg/m2, and at least 1 of the following weight-related comorbidities at screening:; hypertension; dyslipidemia; obstructive sleep apnea; Fatty liver; cardiovascular disease; Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Have a self-reported change in body weight >5 kg within 90 days prior to screening; Had chronic or acute pancreatitis any time prior to screening; Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma; Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome.